Primus In News
Regulatory clearances of targeted therapies boost precision oncology
25-12-2025
Nilaya Varma, Co-Founder and Group CEO, Primus Partners, shared his view that these approvals are significant as they mark a shift towards outcome-based, precision-medicine approaches in routine cancer care. He noted that combination immunotherapies, in particular, are expected to improve outcomes for patient segments that previously had limited therapeutic options.
Explore Related Insights
- India’s Maritime Framework Gets Legislative Boost with Coastal Shipping Bill Passage
- India needs to reduce China dependence in rare earth magnet for EV sector | Report
- Reality shows: OTT platforms' next big content battel with TV
- Anthropic Mythos Isn't Out Yet, But It's Already Exposing India's AI Governance Gaps
